Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Shigella

- PMLiVE

Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA

There are currently no approved human vaccines for Lyme disease

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

MHRA approves Valneva’s chikungunya vaccine Ixchiq for use in adults

The chikungunya virus has now been identified in over 110 countries in Europe, Asia, Africa and the Americas

- PMLiVE

Valneva shares positive phase 3 results for chikungunya vaccine in adolescents

The company has submitted label extension applications for Ixchiq in this age group

- PMLiVE

WHO announces priority endemic pathogens for urgent vaccine development

The study identifies the 17 pathogens that regularly cause diseases in communities

- PMLiVE

Pfizer/Valneva share promising results for Lyme disease vaccine candidate

There are currently no approved human vaccines for the bacterial infection

- PMLiVE

Valneva and LimmaTech Biologics partner to advance Shigella vaccine candidate

There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally

- PMLiVE

WHO announces new mRNA vaccine development initiative against human avian influenza

H5N1 was responsible for 889 cases and 463 deaths across 23 countries from 2003 to 2024

- PMLiVE

GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

The companies aim to develop a portfolio of up to ten candidates

- PMLiVE

EC approves Valneva’s single-dose chikungunya vaccine for use in adults

The virus has been identified in over 110 countries in Europe, Asia, Africa and the Americas

- PMLiVE

CHMP recommends Valneva’s chikungunya vaccine for use in adults

If approved, Ixchiq will become the first vaccine available in the EU for the mosquito-borne viral disease

- PMLiVE

Valneva’s single-dose chikungunya vaccine shows promise in adolescents

The mosquito-borne viral disease often causes sudden, large outbreaks with high attack rates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links